Suppr超能文献

造血干细胞移植的使用和趋势的定量和定性差异:一项全球观察性研究。

Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study.

机构信息

The European Group for Blood and Marrow Transplantation (EBMT) Transplant Activity Survey Office, University Hospital, Basel, Switzerland.

出版信息

Haematologica. 2013 Aug;98(8):1282-90. doi: 10.3324/haematol.2012.076349. Epub 2013 Mar 18.

Abstract

Fifty-five years after publication of the first hematopoietic stem cell transplantation this technique has become an accepted treatment option for defined hematologic and non-hematologic disorders. There is considerable interest in understanding differences in its use and trends on a global level and the macro-economic factors associated with these differences. Data on the numbers of hematopoietic stem cell transplants performed in the 3-year period 2006-2008 were obtained from Worldwide Network for Blood and Marrow Transplantation member registries and from transplant centers in countries without registries. Population and macro-economic data were collected from the World Bank and from the International Monetary Fund. Transplant rates were analyzed by indication, donor type, country, and World Health Organization regional offices areas and related to selected health care indicators using single and multiple linear regression analyses. Data from a total of 146,808 patients were reported by 1,411 teams from 72 countries over five continents. The annual number of transplants increased worldwide with the highest relative increase in the Asia Pacific region. Transplant rates increased preferentially in high income countries (P=0.02), not in low or medium income countries. Allogeneic transplants increased for myelodysplasia, chronic lymphocytic leukemia, acute leukemias, and non-malignant diseases but decreased for chronic myelogenous leukemia. Autologous transplants increased for autoimmune and lymphoproliferative diseases but decreased for leukemias and solid tumors. Transplant rates (P<0.01), donor type (P<0.01) aand disease indications (P<0.01) differed significantly between countries and regions. Transplant rates were associated with Gross National Income/capita (P<0.01) but showed a wide variation of explanatory content by donor type, disease indication and World Health Organization region. Hematopoietic stem cell transplantation activity is increasing worldwide. The preferential increase in high income countries, the widening gap between low and high income countries and the significant regional differences suggest that different strategies are required in individual countries to foster hematopoietic stem cell transplantation as an efficient and cost-effective treatment modality.

摘要

55 年前,首例造血干细胞移植术问世,如今该技术已成为治疗特定血液系统和非血液系统疾病的标准疗法。人们对了解全球范围内该技术使用的差异和趋势,以及与其相关的宏观经济因素有着浓厚的兴趣。我们从全球血液和骨髓移植网络的成员登记处和没有登记处的国家的移植中心获得了 2006-2008 年三年内进行的造血干细胞移植数量的数据。人口和宏观经济数据来自世界银行和国际货币基金组织。我们使用单因素和多因素线性回归分析,根据适应证、供者类型、国家和世界卫生组织区域办事处对移植率进行了分析,并将其与选定的卫生保健指标进行了关联。来自五大洲 72 个国家的 146808 名患者的数据由 1411 个团队报告。全世界的移植例数呈逐年增加趋势,亚太地区的相对增长率最高。高收入国家(P=0.02)的移植率优先增加,而低收入和中等收入国家则没有。骨髓增生异常综合征、慢性淋巴细胞白血病、急性白血病和非恶性疾病的异基因移植增加,但慢性髓性白血病的移植减少。自身免疫性和淋巴增生性疾病的自体移植增加,但白血病和实体肿瘤的移植减少。国家和地区之间的移植率(P<0.01)、供者类型(P<0.01)和疾病适应证(P<0.01)存在显著差异。移植率与人均国民总收入(P<0.01)显著相关,但按供者类型、疾病适应证和世界卫生组织区域的不同,解释内容也存在很大差异。造血干细胞移植术在全球范围内的应用正在增加。高收入国家的优先增长、低收入和高收入国家之间的差距不断扩大以及显著的区域差异表明,各国需要采取不同的策略,将造血干细胞移植作为一种高效、具有成本效益的治疗方法。

相似文献

1
Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study.
Haematologica. 2013 Aug;98(8):1282-90. doi: 10.3324/haematol.2012.076349. Epub 2013 Mar 18.
2
Hematopoietic stem cell transplantation: a global perspective.
JAMA. 2010 Apr 28;303(16):1617-24. doi: 10.1001/jama.2010.491.
3
Hematopoietic stem cell transplantation in Europe 1998.
Hematol J. 2000;1(5):333-50. doi: 10.1038/sj.thj.6200046.
6
Changes in the use of hematopoietic stem cell transplantation: a model for diffusion of medical technology.
Haematologica. 2010 Apr;95(4):637-43. doi: 10.3324/haematol.2009.015586.
10
Predictability of hematopoietic stem cell transplantation rates.
Haematologica. 2007 Dec;92(12):1679-86. doi: 10.3324/haematol.11260.

引用本文的文献

1
Unrelated hematopoietic stem cell donor registries: present reality and future prospects.
Curr Opin Hematol. 2024 Nov 1;31(6):251-260. doi: 10.1097/MOH.0000000000000835. Epub 2024 Jul 19.
2
Correlation of various methods of hematopoietic progenitor cell estimation with standard flowcytometric CD34 enumeration.
Asian J Transfus Sci. 2023 Jul-Dec;17(2):195-201. doi: 10.4103/ajts.ajts_33_21. Epub 2022 Dec 12.
3
Haematopoietic Stem Cell Transplant Trends in Pakistan: Activity Survey from Pakistan Bone Marrow Transplant Group.
J Transplant. 2023 Sep 28;2023:8865364. doi: 10.1155/2023/8865364. eCollection 2023.
4
Temporal trends in Hematopoietic Stem Cell Transplantation in Argentina: regional differences that mirror the global reality.
Hematol Transfus Cell Ther. 2023 Apr-Jun;45(2):145-146. doi: 10.1016/j.htct.2023.05.001.
5
Hematopoietic Stem Cell Transplantation, Where Have We Come and Where Do We Go.
Blood Cell Ther. 2020 May 25;3(3):37-43. doi: 10.31547/bct-2019-016. eCollection 2020 Aug 25.
7
Increasing access to allogeneic hematopoietic cell transplant: an international perspective.
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):264-274. doi: 10.1182/hematology.2021000258.
8
Grasping the sword of Damocles.
Blood. 2021 Nov 11;138(19):1792-1793. doi: 10.1182/blood.2021012347.
9
Effects of storage media, supplements and cryopreservation methods on quality of stem cells.
World J Stem Cells. 2021 Sep 26;13(9):1197-1214. doi: 10.4252/wjsc.v13.i9.1197.

本文引用的文献

1
New American Cancer Society process for creating trustworthy cancer screening guidelines.
JAMA. 2011 Dec 14;306(22):2495-9. doi: 10.1001/jama.2011.1800.
3
Health technologies and innovation in the global health arena.
N Engl J Med. 2011 Sep 1;365(9):779-82. doi: 10.1056/NEJMp1108040.
4
High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials.
J Clin Oncol. 2011 Aug 20;29(24):3214-23. doi: 10.1200/JCO.2010.32.5910. Epub 2011 Jul 18.
7
The EBMT risk score.
Bone Marrow Transplant. 2012 Jun;47(6):749-56. doi: 10.1038/bmt.2011.110. Epub 2011 Jun 6.
8
Introduction of a quality management system and outcome after hematopoietic stem-cell transplantation.
J Clin Oncol. 2011 May 20;29(15):1980-6. doi: 10.1200/JCO.2010.30.4121. Epub 2011 Apr 11.
9
The EBMT activity survey 2009: trends over the past 5 years.
Bone Marrow Transplant. 2011 Apr;46(4):485-501. doi: 10.1038/bmt.2011.11. Epub 2011 Feb 28.
10
WHO Guiding Principles on Human Cell, Tissue and Organ Transplantation.
Cell Tissue Bank. 2010 Nov;11(4):413-9. doi: 10.1007/s10561-010-9226-0.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验